A Study of RoActemra/Actemra (Tocilizumab) Versus Placebo in Patients With Systemic Sclerosis

NCT01532869 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

87

Enrollment

INDUSTRY

Sponsor class

Conditions

Sclerosis, Systemic

Interventions

DRUG: Placebo
DRUG: tocilizumab [RoActemra/Actemra]
DRUG: tocilizumab [RoActemra/Actemra]

Sponsor

Hoffmann-La Roche